# Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Canonical URL: https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-to-participate-at-the-btig-13th-annual-medtech-digital-h-67c8b6e2
Ticker: SENS
Company: Senseonics
Source: Senseonics
Published: 2026-01-28 21:05 EST
## Summary

Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and...

## Article Body
Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.

To request a meeting with Senseonics, investors should contact their BTIG representatives.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact Jeremy Feffer LifeSci Advisors investors@senseonics.com
## Recent Company News
- 2026-06-10 12:00 EST — [Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365](https://biopharmsignal.com/news/SENS/senseonics-and-welldoc-partner-to-develop-next-generation-app-for-eversense-365-6acf0328) — Source: Senseonics
- 2026-06-06 21:00 EST — [Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems](https://biopharmsignal.com/news/SENS/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-perfo-37d528e7) — Source: Senseonics
- 2026-06-01 12:00 EST — [Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026](https://biopharmsignal.com/news/SENS/senseonics-highlights-analyst-event-and-oral-presentation-of-eversense-365-real--5826a5ba) — Source: Senseonics
- 2026-05-07 20:01 EST — [Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-first-quarter-2026-financial-results-a7b4bee3) — Source: Senseonics
- 2026-05-04 20:01 EST — [Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/SENS/senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of--0e1d5fdd) — Source: Senseonics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)